18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

This study evaluates a new imaging drug called 18F-MFBG, used in PET/CT scans, to detect neural crest tumors — a group of cancers including neuroblastoma (common in children), pheochromocytoma, and paraganglioma. It compares this new scan to the standard MIBG scan currently used. **You may be eligible if...** - You have a confirmed or suspected neural crest tumor (e.g., neuroblastoma, pheochromocytoma, or paraganglioma) - If you have neuroblastoma, you have had or are scheduled for a standard MIBG scan within 6 months - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You are pregnant, breastfeeding, or may become pregnant - You had surgery between the time of selection and enrollment - Your doctor determines you are not suitable for this study Talk to your doctor to see if this trial is right for you.